Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen BridgeBio Pharma Inc stake
total: 670
Viking Global Investors BBIO trades
- Total transactions:
- 8
- New positions:
- 1
- Reduced:
- 7
- Held since:
- 2019 Q2
- Held for:
- 29 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Ole Andreas Halvorsen holds 9,949,219 BridgeBio Pharma Inc (BBIO) shares with a market value of roughly $741.02M accounting for 2.11% of the overall portfolio. To date, the estimated cost basis is nearly $26.97 for "buy" trades and estimated average "sell" price is $52.91. Viking Global Investors first purchased BBIO in 2019 Q2, initially acquiring about 26.62M shares. Since the initial investment in BridgeBio Pharma Inc (BBIO), Viking Global Investors has made 7 more transactions.
When did Ole Andreas Halvorsen buy BridgeBio Pharma Inc (BBIO)?
Ole Andreas Halvorsen first invested in BridgeBio Pharma Inc (BBIO) in 2019 Q2 at the reported quarter-end price of $26.97 per share.
What's the cost basis of Viking Global Investors's BBIO stake?
The estimated cost basis for BridgeBio Pharma Inc (BBIO) stake is around $26.97 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $26.97
- Weighted AVG sell price:
- $52.91
Ole Andreas Halvorsen's historical trades in BridgeBio Pharma Inc
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
2.11%
|
9,949,219
|
$74.48
|
$741,017,831
|
-15.99% (-1,893,215)
|
-0.39%
|
|
2026 Q1
|
2.46%
|
11,842,434
|
$74.26
|
$879,419,149
|
-17.73% (-2,551,500)
|
-0.5%
|
|
2025 Q4
|
2.92%
|
14,393,934
|
$76.49
|
$1,100,992,012
|
-9.91% (-1,583,915)
|
-0.31%
|
|
2025 Q3
|
2.16%
|
15,977,849
|
$51.94
|
$829,889,477
|
-13.89% (-2,577,526)
|
-0.39%
|
|
2025 Q2
|
2.32%
|
18,555,375
|
$43.18
|
$801,221,093
|
-15.87% (-3,500,000)
|
-0.48%
|
|
2025 Q1
|
2.42%
|
22,055,375
|
$34.57
|
$762,454,314
|
-12.20% (-3,065,616)
|
-0.34%
|
|
2023 Q3
|
2.69%
|
25,120,991
|
$26.37
|
$662,440,533
|
-5.63% (-1,500,000)
|
-0.16%
|
|
2019 Q2
|
3.22%
|
$26.97
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.